Effect of dopamine D3 receptor blockade on renal function and glomerular size in diabetic rats.

Naunyn Schmiedebergs Arch Pharmacol

Department of Pharmacology and Toxicology, Faculty of Medicine, University of Tübingen, Wilhelmstrasse 56, 72074 Tübingen, Germany,

Published: May 2005


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dopamine D2-like receptors, including D2, D3, and D4 receptors, are involved in the regulation of glomerular hyperfiltration due to diabetes mellitus. These hemodynamic alterations represent a risk factor for the later development of diabetic nephropathy. The aim of the present study was to determine whether the D3 receptor subtype modulates the diabetes-induced increase in glomerular filtration rate (GFR) in rats. Renal function was studied in Sprague-Dawley rats 14 days after induction of a moderate diabetes mellitus (DM) by streptozotocin and in non-diabetic controls (CON). Rats were orally treated either with the peripherally acting, selective dopamine D3 receptor antagonist BSF 135170 (BSF, 10 mg/kg per day for 2 weeks) or with vehicle (VHC). Perfusion-fixed kidneys were used for estimation of glomerular volume. In conscious rats, which were treated with BSF, the DM-induced increase in fluid intake, urinary output, and renal sodium excretion was significantly less pronounced than in the vehicle group (DM-VHC). In the clearance experiments, GFR in CON was about 0.84+/-0.04 ml/min per 100 g body weight. The DM-VHC group presented a significant glomerular hyperfiltration (1.09+/-0.04 ml/min per 100 g body weight). Treatment with BSF significantly lowered GFR towards levels of CON. The estimated glomerular volume was 0.73+/-0.03 x 10(6) microm3 in the CON-VHC group and 0.86+/-0.04 x 10(6) microm3 in the DM-VHC animals. Interestingly, treatment with BSF decreased the glomerular volume in both groups. Irrespective of BSF treatment, kidney wet weight related to body weight was about 36% higher in DM animals compared with CON animals. We conclude that dopamine D3 receptors represent a target for the modulation of diabetes-induced glomerular hyperfiltration. Therefore, the results encourage the testing of the possible beneficial effects of long-term D3 receptor blockade on the development of diabetic nephropathy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00210-005-1030-1DOI Listing

Publication Analysis

Top Keywords

glomerular hyperfiltration
12
glomerular volume
12
body weight
12
dopamine receptor
8
receptor blockade
8
renal function
8
glomerular
8
diabetes mellitus
8
development diabetic
8
diabetic nephropathy
8

Similar Publications

Assessment of GFR Estimation Methods in Patients with Obesity.

J Clin Endocrinol Metab

September 2025

AURA (Association pour l'Utilisation du Rein Artificiel dans la région parisienne), F-75014 Paris, France.

Purpose: Obesity is an independent risk factor for chronic kidney disease, and accurate estimation of the glomerular filtration rate (GFR) is crucial. However, limited data are available on the performance of the European Kidney Function Consortium (EKFC) equation in individuals with overweight or obesity. We evaluated the performance of the EKFC equation by comparing its estimated GFR (eGFR) to values obtained from the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and machine learning (ML) models, using measured GFR (mGFR, obtained via plasma iohexol clearance) as a reference standard in a cohort of patients with overweight or obesity.

View Article and Find Full Text PDF

Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have demonstrated renoprotective and cardioprotective benefits beyond their antiglycemic effects. Their potential utility in kidney transplant recipients (KTRs) for preserving graft function and reducing rejection risk is currently under active investigation. Preliminary studies indicate that SGLT-2i therapy stabilizes estimated glomerular filtration rate (eGFR), decreases glomerular hyperfiltration, and improves metabolic outcomes in KTRs.

View Article and Find Full Text PDF

Background: Patients with severe obesity have glomerular hyperfiltration even without the overt renal dysfunction, but improvements are reported with metabolic surgery (MS). However, the mechanism underlying these effects of MS has not been investigated.

Objective: The aim of the present study was to determine whether MS for patients with severe obesity alters retroperitoneal adipose tissue (RAT) and kidney volume (KV), and whether these alterations lead to improvements in renal function and hypertension (HTN).

View Article and Find Full Text PDF

SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases.

Metabolites

August 2025

Grupo de Investigación en Enfermedades Cardiorrenales y Metabólicas, Departamento de Medicina y Cirugía, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, C/Santiago Ramón y Cajal s/n, 46115 Valencia, Spain.

: Sodium-glucose cotransporter-2 inhibitors (SGLT2is), initially developed as antihyperglycemic agents, have emerged as multifunctional therapeutics with profound cardiorenal and metabolic benefits. Their unique insulin-independent mechanism, targeting renal glucose reabsorption, distinguishes them from conventional antidiabetic drugs. : SGLT2is induce glycosuria, reduce hyperglycemia, and promote weight loss through increased caloric excretion.

View Article and Find Full Text PDF

Diabetic kidney disease (DKD) has emerged as the leading cause of chronic kidney disease (CKD) worldwide, surpassing primary glomerular disorders in prevalence. Despite recent therapeutic advances, current treatment strategies primarily alleviate symptoms rather than address the underlying pathogenic mechanisms, highlighting an urgent need for targeted, mechanism-based interventions. The pathogenesis of DKD involves a complex interplay of metabolic, hemodynamic, inflammatory, oxidative, and fibrotic pathways.

View Article and Find Full Text PDF